Edit Content

RetinAI Discovery Platform and AI Tools Aim to Improve Ophthalmic Care

Discovery Passport
Photo courtesy of RetinAI

February 26, 2024

BERN, Switzerland, and BOSTON  — Ikerian AG and RetinAI Inc. US, a developer of software solutions for image processing and artificial intelligence (AI) in ophthalmology, has launched RetinAI Discovery for Clinics, with two product versions to address the needs of ophthalmologists and optometrists.

Discovery for Clinics and its AI models have been designed to accelerate and enhance clinical decision workflows, teleophthalmology management, referral decisions, and patient management.

The vendor-neutral and multi-modality platform harmonizes, aggregates, and connects large datasets on a single, cloud-based repository for data. The data is then automatically analyzed with RetinAI’s CE-marked and research-use-only AI algorithms for accelerated and AI-biomarker-based treatment decisions. The AI models can be processed on DICOM and other formats for OCT and fundus imaging.

Both the ophthalmology and optometry versions of Discovery for Clinics have progression analytics to help track trends in outcomes and provide powerful visualization to patients on the progression of their disease. The platform connects health care stakeholders and patients with Discovery Passport, a feature that allows physicians to securely share with patients their data and remote questionnaires. The platform in both versions supports referral networks and the participation in clinical trials via the collection of real-world data, enabling clinics to generate additional service opportunities.

‍On top of these tools, the ophthalmology version features research-use-only AI models for a more detailed analysis of geographic atrophy and the ability to look at future atrophy progression through the prediction progression model.

‘’Discovery for Clinics is a powerful tool empowering not only physicians with enhanced AI-powered data insights to optimize outcomes and treatments, but also patients, giving them access to their data,’’ said Dr. Carlos Ciller, CEO and co-founder of Ikerian, parent company of RetinAI.

Commenting on Discovery for Ophthalmology Clinics, Associate Professor Dr. Marion R. Munk, MD, PhD, FEBO, senior retinal physician, Augenarzt-Praxisgemeinschaft Gutblick AG said, “RetinAI Discovery and its fast volumetric AI analysis of OCT images and intuitive progression graphs have provided me with new insights into eye diseases, allowing me to build on existing blocks of AI technology to extract my clinical insights quicker.”

‍Regarding Discovery for Optometry Clinics, Dr. Trusit Dave, PhD, BSc (Hons), DipTp (IP), Prof Cert Galuc, MCOptom, FAAO, said, “I have used the RetinAI Discovery platform and find it to be easy to use and provides useful metrics for AMD, in particular analyzing biomarkers associated with AMD to determine better patient referrals.”




Scroll to Top